{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:56:48Z","timestamp":1767193008579,"version":"3.48.0"},"reference-count":24,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371104"],"award-info":[{"award-number":["82371104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science Foundation for Young Scholars of China","award":["82201185"],"award-info":[{"award-number":["82201185"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,21]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid-associated ophthalmopathy (TAO), the most common orbital disease in adults, is an autoimmune disease of the orbital and periorbital tissues. Typical ocular symptoms of TAO include periorbital oedema, conjunctival congestion and oedema, eyelid retraction, exophthalmos, restrictive strabismus, etc. Hypercholesterolaemia is considered one of the modifiable risk factors of TAO. However, it is unclear whether lipid levels are related to TAO activity and severity and the intravenous glucocorticoids (GC) therapeutic effect. The study aims to evaluate the association between initial lipid and lipoprotein levels, the clinical features of TAO and the efficacy of intravenous methylprednisolone in patients with moderate-to-severe TAO, as well as to explore the oxidative stress-related mechanisms involved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This real-world prospective cohort study will recruit 178 patients with moderate-to-severe TAO who receive two intravenous methylprednisolone regimens, respectively. The primary outcome is the improvement in the composite index at 3 months after baseline treatment, with secondary outcomes including other ocular features, changes in serological characteristics and major adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol was approved by the ethics committees of Xiangya Third Hospital of Central South University (Kuai241012) on 29 November 2024. The study will be conducted according to the guidelines of the Declaration of Helsinki. Participants will be informed of the purpose and content of the study and will complete a written informed consent form before being recruited. The findings will be published in peer-reviewed journals as well as in reports of relevant conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Chinese Clinical Trial Registry (ChiCTR2400094094). Registered on 17 December 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098243","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T18:25:28Z","timestamp":1754418328000},"page":"e098243","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Association between initial lipid and lipoprotein levels, oxidative stress indicators and clinical efficacy of intravenous methylprednisolone in moderate-to-severe thyroid-associated ophthalmopathy: protocol for a real-world prospective cohort study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2754-1408","authenticated-orcid":false,"given":"Shenghua","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China"},{"name":"Central South University Xiangya School of Medicine, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3800-6200","authenticated-orcid":false,"given":"Shiyao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China"},{"name":"Department of Ophthalmology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Third Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2025123106452624000_15.8.e098243.1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0548"},{"key":"2025123106452624000_15.8.e098243.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70276-4"},{"key":"2025123106452624000_15.8.e098243.3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479"},{"key":"2025123106452624000_15.8.e098243.4","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(77)90140-4"},{"key":"2025123106452624000_15.8.e098243.5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jpm14070776","article-title":"Thyroid Eye Disease: Advancements in Orbital and Ocular Pathology Management","volume":"14","author":"Scarabosio","year":"2024","journal-title":"J Pers Med"},{"key":"2025123106452624000_15.8.e098243.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434"},{"key":"2025123106452624000_15.8.e098243.7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"2025123106452624000_15.8.e098243.8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"key":"2025123106452624000_15.8.e098243.9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5551\/jat.42531","article-title":"Associations between Socioeconomic Status and the Prevalence and Treatment of Hypercholesterolemia in a General Japanese Population: NIPPON DATA2010","volume":"25","author":"Fujiyoshi","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2025123106452624000_15.8.e098243.10","doi-asserted-by":"crossref","unstructured":"Man REK , Gan AHW , Fenwick EK , et al . Prevalence, determinants and association of unawareness of diabetes, hypertension and hypercholesterolemia with poor disease control in a multi-ethnic Asian population without cardiovascular disease. Popul Health Metrics 2019;17. doi:10.1186\/s12963-019-0197-5","DOI":"10.1186\/s12963-019-0197-5"},{"key":"2025123106452624000_15.8.e098243.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-57884-4","article-title":"Assessment of hypercholesterolemia prevalence and its demographic variations in the Republic of Kazakhstan","volume":"14","author":"Kulimbet","year":"2024","journal-title":"Sci Rep"},{"key":"2025123106452624000_15.8.e098243.12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/thy.2017.0430","article-title":"High Serum Cholesterol Is a Novel Risk Factor for Graves\u2019 Orbitopathy: Results of a Cross-Sectional Study","volume":"28","author":"Sabini","year":"2018","journal-title":"Thyroid"},{"key":"2025123106452624000_15.8.e098243.13","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-011-9472-3"},{"key":"2025123106452624000_15.8.e098243.14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.25.2822"},{"key":"2025123106452624000_15.8.e098243.15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s40618-018-0915-z","article-title":"Relationship between serum cholesterol and Graves\u2019 orbitopathy (GO): a confirmatory study","volume":"41","author":"Lanzolla","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"2025123106452624000_15.8.e098243.16","doi-asserted-by":"crossref","first-page":"609895","DOI":"10.3389\/fendo.2020.609895","article-title":"Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves\u2019 Ophthalmopathy to Parenteral Corticosteroids","volume":"11","author":"Naselli","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025123106452624000_15.8.e098243.17","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.6.773"},{"key":"2025123106452624000_15.8.e098243.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1568-9972(02)00059-9"},{"key":"2025123106452624000_15.8.e098243.19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/ETJ-23-0109","article-title":"Predicting glucocorticoid effectiveness in thyroid eye disease: combined value from serological lipid metabolism and an orbital MRI parameter","volume":"13","author":"Zhang","year":"2024","journal-title":"Eur Thyroid J"},{"key":"2025123106452624000_15.8.e098243.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2025123106452624000_15.8.e098243.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2393"},{"key":"2025123106452624000_15.8.e098243.22","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/cts.12999","article-title":"Influence of 4\u2010week or 12\u2010week glucocorticoid treatment on metabolic changes in patients with active moderate\u2010to\u2010severe thyroid\u2010associated ophthalmopathy","volume":"14","author":"Chen","year":"2021","journal-title":"Clinical Translational Sci"},{"key":"2025123106452624000_15.8.e098243.23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1089\/thy.2023.0656","article-title":"Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials","volume":"34","author":"Kahaly","year":"2024","journal-title":"Thyroid"},{"key":"2025123106452624000_15.8.e098243.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72787-4"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:45:55Z","timestamp":1767192355000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,5]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2024-098243"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098243","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}